Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance

Jeff Rytlewski; Qierra R. Brockman; Rebecca D. Dodd; Mohammed Milhem; Varun Monga

doi:10.20517/cdr.2021.88

Back

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance

Journal article

Open access

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance

Jeff Rytlewski, Qierra R. Brockman, Rebecca D. Dodd, Mohammed Milhem and Varun Monga

Cancer Drug Resistance, Vol.5(1), pp.25-35

01/04/2022

DOI: 10.20517/cdr.2021.88

PMCID: PMC8992584

PMID: 35582536

Files and links (1)

url

https://doi.org/10.20517/cdr.2021.88View

Published (Version of record) Open Access

Abstract

Sarcomas are a class of rare malignancies of mesenchymal origin with a heterogeneous histological spectrum. They are classically associated with poor outcomes, especially once metastasized. A path to improving clinical outcomes may be made through modifying the epigenome, where a variety of sarcomas demonstrate changes that contribute to their oncogenic phenotypes. This Perspective article identifies and describes changes in the sarcoma genome, while discussing specific epigenetic changes and their effect on clinical outcomes. Clinical attempts at modulating epigenetics in sarcoma are reviewed, as well as potential implications of these studies. Epigenetic targets to reverse and delay chemotherapy resistance are discussed. Future directions with primary next steps are proposed to invigorate the current understanding of epigenetic biomarkers to enact targeted therapies to epigenetic phenotypes of sarcoma subtypes. Modifications to prior studies, as well as proposed clinical steps, are also addressed.

Epigenetics

metastasis

resistance

sarcoma

Details

Title: Subtitle: Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
Creators: Jeff Rytlewski - Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
Qierra R. Brockman - University of Iowa
Rebecca D. Dodd - University of Iowa
Mohammed Milhem - University of Iowa
Varun Monga - University of Iowa
Resource Type: Journal article
Publication Details: Cancer Drug Resistance, Vol.5(1), pp.25-35
DOI: 10.20517/cdr.2021.88
PMID: 35582536
PMCID: PMC8992584
NLM abbreviation: Cancer Drug Resist
ISSN: 2578-532X
eISSN: 2578-532X
Publisher: OAE Publishing Inc
Language: English
Date published: 01/04/2022
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984360049202771

Metrics

13 Record Views

3 Times Cited - Web of Science

See more details